MicroPort® Toumai® Endoscopic Robot Combined with Intraoperative Ultrasound Completes Partial Nephrectomy for Completely Endophytic Renal Tumor

Shanghai, China, the Toumai® Endoscopic Surgery Robotic System (Toumai® Endoscopic Robot), a proprietary product of Shanghai MicroPort MedBot (Shanghai) Co., Ltd. (MicroPort® MedBot), a Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) subsidiary, has now enabled the successful completion of a complex partial nephrectomy for renal tumor, at the Renji Hospital affiliated to Shanghai Jiaotong University.

A team led by Dr. Wei Xue, Head of the Department of Urology, performed the operation, Renji Hospital affiliated to Shanghai Jiaotong University, and Prof. Jiahua Pan of the same department. The domestic Toumai® Endoscopic Robot has been used in various difficult urological surgeries such as radical prostate cancer surgeries and partial nephrectomy, demonstrating its technical strength and value in clinical applications.

Director Xue commented after the operation, “The renal tumor in this case is completely endophytic, meaning it is completely surrounded by renal parenchyma. This made it difficult to precisely locate and identify the tumor boundary solely by visual observation. Hence, the operation needed to be performed in combination with intraoperative ultrasound. The excellent high-definition 3D field of view and smooth control performance of Toumai® reliably guaranteed the successful completion of this complex partial nephrectomy for renal tumor.”

The patient, a 70-year-old woman, sought medical treatment at the Department of Urology, Renji Hospital (affiliated to Shanghai Jiaotong University) after being diagnosed with a 3*4 cm space-occupying lesion in the lower pole of her right kidney. The team led by Dr. Xue considered the possibility of renal cancer based on the results of pre-operative examinations, and decided to perform robot-assisted retroperitoneal approach to partial nephrectomy using the Toumai® Endoscopic Robot. During the operation, Dr Xue completely removed the tumor with the help of the high-definition 3D vision and flexible surgical instruments provided by Toumai®. The operation lasted for a total of 1.5 hours with less than 50ml of bleeding.

Dr. Chao He, President of MicroPort® MedBot said, “Experts at the Renji Hospital affiliated to Shanghai Jiaotong University have completed 10 difficult urological surgeries assisted by the Toumai® Endoscopic Robot, including radical prostate cancer surgeries and partial nephrectomy. Marking a new chapter in our clinical trial program, these surgeries have promoted further clinical breakthroughs by the Toumai® Endoscopic Robot in the field of urology. MicroPort® MedBot will continue to work with clinical experts to provide universally accessible, intelligent total surgical solutions to save patients’ lives or reshape their quality of life.”